AbbVie is reportedly in advanced talks to acquire cancer drugmaker Revolution Medicines. The potential acquisition, aimed at bolstering AbbVie's oncology business, has significantly boosted Revolution Medicines' stock, which surged nearly 30%. This move aligns with AbbVie's strategy to expand its drug development pipeline and strengthen its position in the competitive pharmaceutical market.